STATEMENT OF NEED/TARGET AUDIENCE

Colorectal cancer is among the most common types of cancer in the United States, and the arena of colorectal cancer treatment continues to evolve. Published results from ongoing clinical trials lead to the emergence of new therapeutic agents and regimens and changes in the indications, doses and schedules for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances.

To bridge the gap between research and patient care, Colorectal Cancer Update utilizes one-on-one discussions with leading oncology investigators. By providing access to the latest research developments and expert perspectives, this CME activity assists medical oncologists with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Evaluate the role of K-ras mutations in the selection of patients with colorectal cancer (CRC) for treatment with EGFR inhibitors.
• Develop an evidence-based algorithm for the treatment of metastatic CRC that incorporates bevacizumab, cetuximab and other biologic agents, based on an understanding of the efficacy and tolerability of these regimens.
• Develop an evidence-based algorithm for the adjuvant treatment of localized Stage II and Stage III colon cancer, based on an understanding of the benefits and risks of adjuvant systemic therapy.
• Summarize clinical factors that influence decisions about resectability of hepatic CRC metastases in order to facilitate identification of patients who may benefit from surgery.
• Evaluate the role of perioperative chemotherapy and surgery versus surgery alone to assist in treatment planning for patients with resectable hepatic CRC metastases.
• Counsel appropriately selected patients about the availability of ongoing clinical trials in which they may be eligible to participate.

PURPOSE OF THIS ISSUE OF COLORECTAL CANCER UPDATE

The purpose of Issue 2 of Colorectal Cancer Update is to support the learning objectives by offering the perspectives of Drs Geller, Grothey, Mayer, Meropol, Van Cutsem and Venook on the integration of emerging clinical research data into the management of colorectal cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs, review the Internet content and complete the Post-test and Evaluation Form located at www.ColorectalCancerUpdate.com/CME. www.ColorectalCancerUpdate.com contains edited comments, clinical trial schemas, graphics and references that supplement the audio program, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

This program is supported by educational grants from Genentech BioOncology and Sanofi-Aventis.

.